Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jazz to expand with Orphan buy
Under the agreement, which was unanimously approved by Orphan Medical’s board of directors, Orphan Medical common stockholders will receive $10.75 per share in cash upon the close of
Under the agreement, which was unanimously approved by Orphan Medical’s board of directors, Orphan Medical common stockholders will receive $10.75 per share in cash upon the close of
Gefitinib (marketed as Iressa by AstraZeneca) has been recently approved for clinical treatment of patients with advanced non-small cell lung cancer (NSCLC) and is an inhibitor of epidermal
Pfizer’s first-quarter net income was $301 million, or 4 cents a share, compared to $2.33 billion, or 30 cents a share, last year. Revenues for the first quarter
The organizations’ first common award program is seeking applications focused on technologies that can achieve selective targeting and/or delivery of therapeutic agents to specific regions or cells in
The FDA has now approved an investigational new drug (IND) application for a phase II study of AS1404 in hormone-refractory prostate cancer. This study, in which AS1404 will
The preclinical data were presented at the American Association for Cancer Research (AACR) annual meeting in Anaheim, California. ImmunoGen developed this CD33-targeting compound for the treatment of acute
The analysis, from researchers at North Shore University Hospital in New York and the University of Michigan Cardiovascular Center, estimates that patients treated with the intravenous drug nesiritide
The clinical trial, which was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, was designed to compare AstraZeneca’s Iressa (gefitinib) to placebo
Collegium’s business model is to develop differentiated, patent-protected or high barrier to entry products, complete ‘proof of concept’ studies and then out-license the products for commercialization by a
Vinorelbine tartrate 10mg (base)/mL is indicated as a single agent or in combination with cisplatin for the first line treatment of ambulatory patients with unresectable, advanced non-small cell